Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
F 4.315 -3.68% -0.17
ATNX closed down 3.68 percent on Friday, March 5, 2021, on 1.86 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ATNX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Older End-of-Day Signals for ATNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Athenex, Inc. Description

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancers Oncology Organic Compounds Chemotherapy Radiation Antineoplastic Drugs Organic Chemistry Dermatitis Therapies For Cancer Nausea Vomiting Docetaxel Pruritus Scars Treatment Of Various Types Of Cancers

Is ATNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 15.24
52 Week Low 3.9701
Average Volume 2,559,450
200-Day Moving Average 12.07
50-Day Moving Average 11.61
20-Day Moving Average 10.91
10-Day Moving Average 8.44
Average True Range 1.00
ADX 35.87
+DI 8.25
-DI 54.52
Chandelier Exit (Long, 3 ATRs ) 12.00
Chandelier Exit (Short, 3 ATRs ) 6.97
Upper Bollinger Band 18.05
Lower Bollinger Band 3.77
Percent B (%b) 0.04
BandWidth 130.95
MACD Line -2.03
MACD Signal Line -1.05
MACD Histogram -0.9786
Fundamentals Value
Market Cap 402.76 Million
Num Shares 93.3 Million
EPS -2.06
Price-to-Earnings (P/E) Ratio -2.10
Price-to-Sales 7.10
Price-to-Book 5.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.12
Resistance 3 (R3) 5.10 4.80 4.99
Resistance 2 (R2) 4.80 4.60 4.81 4.94
Resistance 1 (R1) 4.56 4.47 4.41 4.58 4.90
Pivot Point 4.26 4.26 4.19 4.28 4.26
Support 1 (S1) 4.02 4.06 3.87 4.05 3.73
Support 2 (S2) 3.73 3.93 3.74 3.69
Support 3 (S3) 3.48 3.73 3.64
Support 4 (S4) 3.51